Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid com­mer­cial prep

A chunky chain neck­lace, match­ing ear­rings, and a flo­ral shirt with a dozen col­ors — that’s Ig­or Splaws­ki.

The for­mer chief sci­en­tist at Cure­Vac has tak­en his RNA ex­per­tise — and fash­ion — to RTW In­vest­ments’ stealth start­up Yarrow Biotech­nol­o­gy, be­com­ing its new CSO. Yarrow, just like RTW, is based in New York City. The ear­ly-stage biotech is de­vel­op­ing an­ti­sense oligonu­cleotide treat­ments for mono­genic CNS dis­eases, though it won’t dis­close ex­act­ly what in­di­ca­tions it’s look­ing at.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.